Increased global integration in the brain after psilocybin therapy for depression.


Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
04 2022
Historique:
received: 10 05 2021
accepted: 14 02 2022
pubmed: 13 4 2022
medline: 22 4 2022
entrez: 12 4 2022
Statut: ppublish

Résumé

Psilocybin therapy shows antidepressant potential, but its therapeutic actions are not well understood. We assessed the subacute impact of psilocybin on brain function in two clinical trials of depression. The first was an open-label trial of orally administered psilocybin (10 mg and 25 mg, 7 d apart) in patients with treatment-resistant depression. Functional magnetic resonance imaging (fMRI) was recorded at baseline and 1 d after the 25-mg dose. Beck's depression inventory was the primary outcome measure ( MR/J00460X/1 ). The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients with major depressive disorder received either 2 × 25 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo ('psilocybin arm') or 2 × 1 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily escitalopram (10-20 mg) ('escitalopram arm'). fMRI was recorded at baseline and 3 weeks after the second psilocybin dose ( NCT03429075 ). In both trials, the antidepressant response to psilocybin was rapid, sustained and correlated with decreases in fMRI brain network modularity, implying that psilocybin's antidepressant action may depend on a global increase in brain network integration. Network cartography analyses indicated that 5-HT2A receptor-rich higher-order functional networks became more functionally interconnected and flexible after psilocybin treatment. The antidepressant response to escitalopram was milder and no changes in brain network organization were observed. Consistent efficacy-related brain changes, correlating with robust antidepressant effects across two studies, suggest an antidepressant mechanism for psilocybin therapy: global increases in brain network integration.

Identifiants

pubmed: 35411074
doi: 10.1038/s41591-022-01744-z
pii: 10.1038/s41591-022-01744-z
doi:

Substances chimiques

Antidepressive Agents 0
Hallucinogens 0
Psilocybin 2RV7212BP0
Escitalopram 4O4S742ANY

Banques de données

ClinicalTrials.gov
['NCT03429075']

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

844-851

Subventions

Organisme : Medical Research Council
ID : MR/J00460X/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Depression and Other Common Mental Disorders: Global Health Estimates (World Health Organization, 2017).
Tang, F. et al. COVID-19 related depression and anxiety among quarantined respondents. Psychol. Health 36, 164–178 (2021).
pubmed: 32567952 doi: 10.1080/08870446.2020.1782410
Rabeea, S. A., Merchant, H. A., Khan, M. U., Kow, C. S. & Hasan, S. S. Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. DARU J. Pharm. Sci. https://doi.org/10.1007/s40199-021-00390-z (2021).
Hofmann, S. G., Curtiss, J., Carpenter, J. K. & Kind, S. Effect of treatments for depression on quality of life: a meta-analysis. Cogn. Behav. Ther. 46, 265–286 (2017).
pubmed: 28440699 pmcid: 5663193 doi: 10.1080/16506073.2017.1304445
Locher, C. et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry 74, 1011 (2017).
pubmed: 28854296 pmcid: 5667359 doi: 10.1001/jamapsychiatry.2017.2432
Haddad, P. The SSRI discontinuation syndrome. J. Psychopharmacol. 12, 305–313 (1998).
pubmed: 10958258 doi: 10.1177/026988119801200311
Steinert, C., Hofmann, M., Kruse, J. & Leichsenring, F. Relapse rates after psychotherapy for depression – stable long-term effects? A meta-analysis. J. Affect. Disord. 168, 107–118 (2014).
pubmed: 25043322 doi: 10.1016/j.jad.2014.06.043
Nutt, D. & Carhart-Harris, R. The current status of psychedelics in psychiatry. JAMA Psychiatry https://doi.org/10.1001/jamapsychiatry.2020.2171 (2020).
Lyons, T. & Carhart-Harris, R. L. More realistic forecasting of future life events after psilocybin for treatment-resistant depression. Front. Psychol. 9, 1721 (2018).
pubmed: 30369890 pmcid: 6194345 doi: 10.3389/fpsyg.2018.01721
Beck, A. T. & Clark, D. A. Anxiety and depression: an information processing perspective. Anxiety Res. 1, 23–36 (1988).
doi: 10.1080/10615808808248218
Rolls, E. T. A non-reward attractor theory of depression. Neurosci. Biobehav. Rev. 68, 47–58 (2016).
pubmed: 27181908 doi: 10.1016/j.neubiorev.2016.05.007
Hamilton, J. P. et al. Default-mode and task-positive network activity in major depressive disorder: implications for adaptive and maladaptive rumination. Biol. Psychiatry 70, 327–333 (2011).
pubmed: 21459364 pmcid: 3144981 doi: 10.1016/j.biopsych.2011.02.003
Kendler, K. S. The phenomenology of major depression and the representativeness and nature of DSM criteria. Am. J. Psychiatry 173, 771–780 (2016).
pubmed: 27138588 doi: 10.1176/appi.ajp.2016.15121509
Goodman, Z. et al. Whole-brain functional dynamics track depressive symptom severity. Cereb. Cortex https://doi.org/10.1093/cercor/bhab047 (2021).
Margulies, D. S. et al. Situating the default-mode network along a principal gradient of macroscale cortical organization. Proc. Natl Acad. Sci. USA 113, 12574–12579 (2016).
pubmed: 27791099 pmcid: 5098630 doi: 10.1073/pnas.1608282113
Andrews-Hanna, J. R., Smallwood, J. & Spreng, R. N. The default network and self-generated thought: component processes, dynamic control, and clinical relevance: the brain’s default network. Ann. NY Acad. Sci. 1316, 29–52 (2014).
pubmed: 24502540 doi: 10.1111/nyas.12360
Lydon-Staley, D. M. et al. Repetitive negative thinking in daily life and functional connectivity among default mode, fronto-parietal, and salience networks. Transl. Psychiatry 9, 234 (2019).
pubmed: 31534117 pmcid: 6751201 doi: 10.1038/s41398-019-0560-0
Daws, R. E. et al. Optimisation of brain states and behavioural strategies when learning complex tasks. Preprint at bioRxiv https://doi.org/10.1101/2020.06.17.156570 (2021).
Kim, C., Cilles, S. E., Johnson, N. F. & Gold, B. T. Domain general and domain preferential brain regions associated with different types of task switching: a meta-analysis. Hum. Brain Mapp. 33, 130–142 (2012).
pubmed: 21391260 doi: 10.1002/hbm.21199
Turnbull, A. et al. Reductions in task-positive neural systems occur with the passage of time and are associated with changes in ongoing thought. Sci. Rep. 10, 9912 (2020).
pubmed: 32555212 pmcid: 7303126 doi: 10.1038/s41598-020-66698-z
Wilkinson, P. O. & Goodyer, I. M. Attention difficulties and mood-related ruminative response style in adolescents with unipolar depression. J. Child Psychol. Psychiatry https://doi.org/10.1111/j.1469-7610.2006.01660.x (2006).
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9, 3897–3902 (1998).
pubmed: 9875725 doi: 10.1097/00001756-199812010-00024
Beliveau, V. et al. The structure of the serotonin system: a PET imaging study. NeuroImage 205, 116240 (2020).
pubmed: 31600591 doi: 10.1016/j.neuroimage.2019.116240
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J. & Erritzoe, D. Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern‐era clinical studies. Acta Psychiatr. Scand. 143, 101–118 (2021).
pubmed: 33125716 doi: 10.1111/acps.13249
Carhart-Harris, R. L. et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci. Rep. 7, 13187 (2017).
pubmed: 29030624 pmcid: 5640601 doi: 10.1038/s41598-017-13282-7
Carhart-Harris, R. L. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402–1411 (2021).
pubmed: 33852780 doi: 10.1056/NEJMoa2032994
Nutt, D., Erritzoe, D. & Carhart-Harris, R. Psychedelic psychiatry’s brave new world. Cell 181, 24–28 (2020).
pubmed: 32243793 doi: 10.1016/j.cell.2020.03.020
Carhart-Harris, R. L. & Friston, K. J. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol. Rev. 71, 316–344 (2019).
pubmed: 31221820 pmcid: 6588209 doi: 10.1124/pr.118.017160
Lord, L.-D. et al. Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. NeuroImage 199, 127–142 (2019).
pubmed: 31132450 doi: 10.1016/j.neuroimage.2019.05.060
Luppi, A. I. et al. LSD alters dynamic integration and segregation in the human brain. NeuroImage 227, 117653 (2021).
pubmed: 33338615 doi: 10.1016/j.neuroimage.2020.117653
Carhart-Harris, R. L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl Acad. Sci. USA 109, 2138–2143 (2012).
pubmed: 22308440 pmcid: 3277566 doi: 10.1073/pnas.1119598109
Fried, E. I. The 52 symptoms of major depression: lack of content overlap among seven common depression scales. J. Affect. Disord. 208, 191–197 (2017).
pubmed: 27792962 doi: 10.1016/j.jad.2016.10.019
Mattar, M. G., Cole, M. W., Thompson-Schill, S. L. & Bassett, D. S. A functional cartography of cognitive systems. PLoS Comput. Biol. 11, e1004533 (2015).
pubmed: 26629847 pmcid: 4668064 doi: 10.1371/journal.pcbi.1004533
Mucha, P. J., Richardson, T., Macon, K., Porter, M. A. & Onnela, J.-P. Community structure in time-dependent, multiscale, and multiplex networks. Science 328, 876–878 (2010).
pubmed: 20466926 doi: 10.1126/science.1184819
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J. & Griffiths, R. R. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci. Rep. 10, 2214 (2020).
pubmed: 32042038 pmcid: 7010702 doi: 10.1038/s41598-020-59282-y
Pasquini, L., Palhano-Fontes, F. & Araujo, D. B. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J. Psychopharmacol. 34, 623–635 (2020).
pubmed: 32255395 doi: 10.1177/0269881120909409
Parkes, L., Satterthwaite, T. D. & Bassett, D. S. Towards precise resting-state fMRI biomarkers in psychiatry: synthesizing developments in transdiagnostic research, dimensional models of psychopathology, and normative neurodevelopment. Curr. Opin. Neurobiol. 65, 120–128 (2020).
pubmed: 33242721 pmcid: 7770086 doi: 10.1016/j.conb.2020.10.016
Ye, M. et al. Changes of functional brain networks in major depressive disorder: a graph theoretical analysis of resting-state fMRI. PLoS ONE 10, e0133775 (2015).
pubmed: 26327292 pmcid: 4556670 doi: 10.1371/journal.pone.0133775
Feurer, C. et al. Resting state functional connectivity correlates of rumination and worry in internalizing psychopathologies. Depress. Anxiety https://doi.org/10.1002/da.23142 (2021).
Roseman, L. et al. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J. Psychopharmacol. 33, 1076–1087 (2019).
pubmed: 31294673 doi: 10.1177/0269881119855974
Watts, R., Day, C., Krzanowski, J., Nutt, D. & Carhart-Harris, R. Patients’ accounts of increased ‘connectedness’ and ‘acceptance’ after psilocybin for treatment-resistant depression. J. Humanist. Psychol. 57, 520–564 (2017).
doi: 10.1177/0022167817709585
Murphy-Beiner, A. & Soar, K. Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacol. 237, 1161–1169 (2020).
doi: 10.1007/s00213-019-05445-3
Zeifman, R. J. et al. Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front. Psychiatry 11, 782 (2020).
pubmed: 32903724 pmcid: 7438781 doi: 10.3389/fpsyt.2020.00782
Carhart-Harris, R. L. & Nutt, D. J. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091–1120 (2017).
pubmed: 28858536 pmcid: 5606297 doi: 10.1177/0269881117725915
Wang, X., Öngür, D., Auerbach, R. P. & Yao, S. Cognitive vulnerability to major depression: view from the intrinsic network and cross-network interactions. Harv. Rev. Psychiatry 24, 188–201 (2016).
pubmed: 27148911 pmcid: 4859203 doi: 10.1097/HRP.0000000000000081
Hampshire, A. et al. Probing cortical and sub-cortical contributions to instruction-based learning: regional specialisation and global network dynamics. NeuroImage 192, 88–100 (2019).
pubmed: 30851447 doi: 10.1016/j.neuroimage.2019.03.002
Soreq, E., Violante, I. R., Daws, R. E. & Hampshire, A. Neuroimaging evidence for a network sampling theory of individual differences in human intelligence test performance. Nat. Commun. 12, 2072 (2021).
pubmed: 33824305 pmcid: 8024400 doi: 10.1038/s41467-021-22199-9
Watanabe, T. & Rees, G. Brain network dynamics in high-functioning individuals with autism. Nat. Commun. 8, 16048 (2017).
pubmed: 28677689 pmcid: 5504272 doi: 10.1038/ncomms16048
Gu, B.-M. et al. Neural correlates of cognitive inflexibility during task-switching in obsessive–compulsive disorder. Brain 131, 155–164 (2007).
pubmed: 18065438 doi: 10.1093/brain/awm277
Wei, M. et al. Abnormal dynamic community structure of the salience network in depression: abnormal salience network in depression. J. Magn. Reson. Imaging 45, 1135–1143 (2017).
pubmed: 27533068 doi: 10.1002/jmri.25429
Carhart-Harris, R. L. et al. Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? J. Psychopharmacol. https://doi.org/10.1177/02698811211008567 (2021).
Carhart-Harris, R. L. et al. Psychedelics and the essential importance of context. J. Psychopharmacol. 32, 725–731 (2018).
pubmed: 29446697 doi: 10.1177/0269881118754710
Tagliazucchi, E. & Laufs, H. Decoding wakefulness levels from typical fMRI resting-state data reveals reliable drifts between wakefulness and sleep. Neuron 82, 695–708 (2014).
pubmed: 24811386 doi: 10.1016/j.neuron.2014.03.020
Leonardi, N. & Van De Ville, D. On spurious and real fluctuations of dynamic functional connectivity during rest. NeuroImage 104, 430–436 (2015).
pubmed: 25234118 doi: 10.1016/j.neuroimage.2014.09.007
Finc, K. et al. Dynamic reconfiguration of functional brain networks during working memory training. Nat. Commun. 11, 2435 (2020).
pubmed: 32415206 pmcid: 7229188 doi: 10.1038/s41467-020-15631-z
Jack, C. R. et al. The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 27, 685–691 (2008).
pubmed: 18302232 pmcid: 2544629 doi: 10.1002/jmri.21049
Smith, S. M. et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage 23, S208–S219 (2004).
pubmed: 15501092 doi: 10.1016/j.neuroimage.2004.07.051
Cox, R. W. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res. 29, 162–173 (1996).
pubmed: 8812068 doi: 10.1006/cbmr.1996.0014
Dale, A. M., Fischl, B. & Sereno, M. I. Cortical surface-based analysis. NeuroImage 9, 179–194 (1999).
pubmed: 9931268 doi: 10.1006/nimg.1998.0395
Avants, B. B., Tustison, N. & Song, G. Advanced normalization tools (ANTs). Insight J. 2, 1–35 (2009).
Schaefer, A. et al. Local-global parcellation of the human cerebral cortex from intrinsic functional connectivity MRI. Cereb. Cortex 28, 3095–3114 (2018).
pubmed: 28981612 doi: 10.1093/cercor/bhx179
Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. J. Stat. Mech. Theory Exp. 2008, P10008 (2008).
doi: 10.1088/1742-5468/2008/10/P10008
Newman, M. E. J. & Girvan, M. Finding and evaluating community structure in networks. Phys. Rev. E 69, 026113 (2004).
doi: 10.1103/PhysRevE.69.026113
Bassett, D. S. et al. Task-based core-periphery organization of human brain dynamics. PLoS Comput. Biol. 9, e1003171 (2013).
pubmed: 24086116 pmcid: 3784512 doi: 10.1371/journal.pcbi.1003171
Maslov, S. & Sneppen, K. Specificity and stability in topology of protein networks. Science 296, 910–913 (2002).
pubmed: 11988575 doi: 10.1126/science.1065103
Rubinov, M. & Sporns, O. Weight-conserving characterization of complex functional brain networks. NeuroImage 56, 2068–2079 (2011).
pubmed: 21459148 doi: 10.1016/j.neuroimage.2011.03.069

Auteurs

Richard E Daws (RE)

The Computational, Cognitive and Clinical Neuroimaging Laboratory (C3NL), Imperial College London, London, UK. richard.daws@kcl.ac.uk.
Centre for Neuroimaging Sciences, Kings College London, London, UK. richard.daws@kcl.ac.uk.

Christopher Timmermann (C)

The Computational, Cognitive and Clinical Neuroimaging Laboratory (C3NL), Imperial College London, London, UK.
Centre for Psychedelic Research, Division of Academic Psychiatry, Imperial College London, London, UK.

Bruna Giribaldi (B)

Centre for Psychedelic Research, Division of Academic Psychiatry, Imperial College London, London, UK.

James D Sexton (JD)

Centre for Psychedelic Research, Division of Academic Psychiatry, Imperial College London, London, UK.

Matthew B Wall (MB)

Invicro London, Hammersmith Hospital, London, UK.
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Clinical Psychopharmacology Unit, University College London, London, UK.

David Erritzoe (D)

Centre for Psychedelic Research, Division of Academic Psychiatry, Imperial College London, London, UK.

Leor Roseman (L)

Centre for Psychedelic Research, Division of Academic Psychiatry, Imperial College London, London, UK.

David Nutt (D)

Centre for Psychedelic Research, Division of Academic Psychiatry, Imperial College London, London, UK.

Robin Carhart-Harris (R)

Centre for Psychedelic Research, Division of Academic Psychiatry, Imperial College London, London, UK.
Psychedelics Division, Neuroscape, Department of Neurology, University of California, San Francisco, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH